Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shinichiro Fuma"'
Publikováno v:
Journal of Pharmacological Sciences, Vol 134, Iss 2, Pp 86-92 (2017)
Kallidinogenase has been used to treat retinal vein occlusion (RVO) in patients, although there are no evidences on the effects of kallidinogenase on the retinal edema and the non-perfused areas in eyes with a RVO. We have established a murine RVO mo
Externí odkaz:
https://doaj.org/article/e557ce25fd0c42a3b3964cccc7848141
Autor:
Shinichiro Fuma, Yae Hidaka, Anri Nishinaka, Hiroto Yasuda, Kota Aoshima, Shinsuke Nakamura, Hideaki Hara, Masamitsu Shimazawa
Publikováno v:
Molecular Vision; 2023, Vol. 29, p188-196, 9p
Autor:
Shinichiro Fuma, Masamitsu Shimazawa, Yuki Inoue, Shinsuke Nakamura, Anri Nishinaka, Yoshifumi Hida, Hideaki Hara
Publikováno v:
Investigative ophthalmologyvisual science. 59(11)
Purpose To determine the relationship between retinal morphologic changes and molecules involved in the changes after anti-VEGF treatment in the retina of retinal vein occlusion (RVO) murine model. Methods The studies were performed on murine RVO mod
Autor:
Shinichiro Fuma, Tomoyo Imamura, Masamitsu Shimazawa, Kazuhiro Tsuruma, Yusuke Kanno, Hideaki Hara, Norihito Takano
Publikováno v:
Biological & Pharmaceutical Bulletin. 39:192-198
The combination of timolol and latanoprost, which are ocular hypotensive agents, has a greater ocular hypotensive effect than each as monotherapy. However, the protective effect of the combination is not well understood. In the present study, we inve
Publikováno v:
Journal of Pharmacological Sciences, Vol 134, Iss 2, Pp 86-92 (2017)
Kallidinogenase has been used to treat retinal vein occlusion (RVO) in patients, although there are no evidences on the effects of kallidinogenase on the retinal edema and the non-perfused areas in eyes with a RVO. We have established a murine RVO mo
Autor:
Anri Nishinaka, Masamitsu Shimazawa, Yuki Inoue, Mineo Kondo, Shinichiro Fuma, Kazuhiro Tsuruma, Hideaki Hara
Publikováno v:
Scientific Reports
The mechanism underlying the effects of anti-vascular endothelial growth factor (VEGF) antibody in retinal vein occlusion (RVO) treatment is poorly understood, partly due to the lack of RVO animal models that mimic clinical pathology. The aims of thi